Research Bridge Partners Appoints New Members to the Company's Board of Directors [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
biomedical startup companies based on the breakthroughs of preeminent innovators at mid-continent research universities, announced the appointment of new members to its board of directors effective July 26, 2024 Ann M. Arvin , M.D. , the Lucille Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology, Emerita at Stanford University Lydia Meyer-Turkson , former Head of North America Public Private Partnerships for Philips, and Matt Tremblay , Ph.D. , CEO of Blackbird Laboratories, have each been appointed to a renewable three-year term. Lydia McClure , Ph.D., who was appointed Chief Executive Officer of Research Bridge Partners on October 4, 2023 , has been appointed Board Chair. "Ann, Lydia and Matt each possess a wealth of experience successfully developing and commercializing biomedical innovations, along with a deep personal conviction to save and improve lives in the process," said McClure. "I'm excited about what we'll accomplish together." Arv
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology Appoints Jason O’Byrne as Chief Financial OfficerBusiness Wire
- Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell EngagersBusiness Wire
- Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceBusiness Wire
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $110.00 price target on the stock.MarketBeat
- Hepatitis B Virus Infection Pipeline Insight Report 2024: Therapeutic Assessment of 80+ Companies and 90+ Drugs [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 8/1/24 - Miss
VIR
Sec Filings
- 9/10/24 - Form 4
- 9/10/24 - Form 8-K
- 9/9/24 - Form 144
- VIR's page on the SEC website